{
    "clinical_study": {
        "@rank": "90557", 
        "arm_group": [
            {
                "arm_group_label": "6 months group", 
                "arm_group_type": "Experimental", 
                "description": "6months duration clopidogrel treatment"
            }, 
            {
                "arm_group_label": "12 months  or longer  group", 
                "arm_group_type": "Experimental", 
                "description": "12 months  or longer duration  clopidogrel treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "1. Objective To test the safety of 6 month-duration of DAPT compared to conventional\n           12-month-or-longer duration after new generation DES implantation in patients with\n           acute coronary syndrome.\n\n        2. Hypothesis A 6-month duration of DAPT is non-inferior to a conventional\n           12-month-or-longer duration of DAPT at preventing the occurrence of major adverse\n           cardiac and cerebrovascular events."
        }, 
        "brief_title": "Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Coronary Syndrome", 
        "condition_browse": {
            "mesh_term": "Acute Coronary Syndrome"
        }, 
        "detailed_description": {
            "textblock": "1. Primary endpoint composite of death, spontaneous MI, stent thrombosis, cerebrovascular\n           events or BARC Type 3, 4 and 5 bleeding over the 6- to 18-month for comparison of\n           6-month vs. 12-month or longer clopidogrel treatment\n\n        2. Secondary endpoint 1) 6- to 18-month each component of primary endpoint 2) 6- to\n           18-month death, or myocardial infarction (MI) 3) 6- to 18-month cardiac death 4) 6- to\n           18-month target vessel failure (TVF) : cardiac death, MI in the target vessel\n           territory, target vessel revascularization (TVR) 5) 6- to 18-month major adverse\n           cardiac and cerebrovascular events (all death, MI, cerebrovascular event,\n           revascularization [MACCE]) 6) 6- to 36-month death, MI, cerebrovascular events, stent\n           thrombosis or BARC Type 3, 4 and 5 bleeding 7) 6- to 60-month death, MI,\n           cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject must be at least 20 years of age.\n\n          2. Subject must have evidence of acute coronary syndrome (e.g., unstable angina, NSTEMI,\n             or STEMI)\n\n          3. Subject is able to verbally confirm understandings of risks, benefits and treatment\n             alternatives of receiving 6-month or 12-month or longer duration of DAPT and he/she\n             or his/her legally authorized representative provides written informed consent prior\n             to any study related procedure.\n\n        Exclusion Criteria:\n\n          1. An elective surgical procedure is planned that would necessitate interruption of\n             thienopyridines during the first 12 months post enrollment.\n\n          2. Patients with cardiogenic shock\n\n          3. Subjects who have dialysis.\n\n          4. Women who are pregnant or breast feeing\n\n          5. Less than 2years life expectancy by previous medical history\n\n          6. Patients with hypersensitivity or contraindications for aspirin or clopidogrel\n\n          7. Patients who need long-tem clopidogrel taking due to cerebral infarction or other\n             diseases\n\n          8. Patients who can not give written consent such as mental illness"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01701453", 
            "org_study_id": "2011-12-070"
        }, 
        "intervention": {
            "arm_group_label": [
                "6 months group", 
                "12 months  or longer  group"
            ], 
            "intervention_name": "clopidogrel", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Clopidogrel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "duration of DAPT", 
        "lastchanged_date": "December 7, 2013", 
        "location": [
            {
                "contact": {
                    "email": "hcgwon@skku.edu", 
                    "last_name": "Hyoen-Cheol Gwon, PhD", 
                    "phone": "82-2-3410-3418"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "investigator": {
                    "last_name": "Hyoen-Cheol Gwon, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hc.gwon@samsung.com", 
                    "last_name": "Hyeon-Cheol Gwon, MD, PhD", 
                    "phone": "82-2-3410-3418"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "135-710"
                    }, 
                    "name": "Samsung Medical Center"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)", 
        "overall_contact": {
            "email": "hcgwon@skku.edu", 
            "last_name": "Hyeon-Cheol Gwon, PhD", 
            "phone": "82-2-3410-3418"
        }, 
        "overall_contact_backup": {
            "email": "youngbin.song@gmail.com", 
            "last_name": "Young Bin Song, MD", 
            "phone": "82-2-3410-3419"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Hyeon-Cheol Gwon, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Composite of death, spontaneous myocardial infarction [MI], cerebrovascular event, stent thrombosis, or BARC Type 3, 4 and 5 bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "over the 6- to 18-month postindex hospitalization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01701453"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Hyeon-Cheol Gwon", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Any cause of death", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Any cause of death or spontaneous MI", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Cardiac death", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Target vessel failure defined as cardiac death, MI in the target vessel territory, target vessel revascularization (TVR)", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Major adverse cardiac and cerebrovascular events [MACCE] defined as all death, MI, cerebrovascular event, any revascularization", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Any cause of death, MI, cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 36-month postindex hospitalization"
            }, 
            {
                "measure": "Any cause of death, MI, cerebrovascular events, stent thrombosis or BARC Type 3, 4 and 5 bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 60-month postindex hospitalization"
            }, 
            {
                "measure": "myocardial infarction", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "Cerebrovascular event", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }, 
            {
                "measure": "BARC Type 3, 4 and 5 bleeding", 
                "safety_issue": "Yes", 
                "time_frame": "over the 6- to 18-month postindex hospitalization"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}